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ABSTRACT 
Objective: Transmission of HIV-1 involves a bottleneck in which generally a single HIV-1 
variant from a diverse viral population in the transmitting partner establishes infection in the 
new host. It is still unclear to what extent this event is driven by specific properties of the 
transmitted viruses or the result of a stochastic process. Our study aimed to better characterize 
this phenomenon and define properties shared by transmitted viruses. 
Design: We compared antigenic and functional properties of envelope glycoproteins of viral 
variants found during primary infection in 27 patients belonging to eight transmission chains.  
Methods: We generated pseudotyped viruses expressing Env variants of the viral quasi-
species infecting each patient and compared their sensitivity to neutralization by eight human 
monoclonal broadly neutralizing antibodies (HuMoNAbs). We also compared their infectious 
properties by measuring their infectivity and sensitivity to various entry inhibitors.  
Results: Transmitted viruses from the same transmission chain shared many properties, 
including similar neutralization profiles, sensitivity to inhibitors, and infectivity, providing 
evidence that the transmission bottleneck is mainly non-stochastic. Transmitted viruses were 
CCR5-tropic, sensitive to MVC, and resistant to soluble forms of CD4, irrespective of the 
cluster to which they belonged. They were also sensitive to HuMoNAbs that target V3, the 
CD4 binding site, and the MPER region, suggesting that the loss of these epitopes may 
compromise their capacity to be transmitted. 
Conclusions: Our data suggest that the transmission bottleneck is governed by selective 
forces. How these forces confer an advantage to the transmitted virus has yet to be 
determined. 
Keywords: HIV transmission, bottleneck, selection, envelope glycoproteins properties 
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INTRODUCTION 
The HIV-1 population found in acute infections is very homogeneous, in contrast to the high 
diversity of the quasispecies observed in chronic infections [1,2]. Several studies concluded 
that sexual transmission of HIV-1 involves a genetic bottleneck, resulting in the transmission 
of a single or limited number of viral variants [2–8].  
Substantial efforts have been made to identify properties that differ between 
transmitted/founder (T/F) and chronic viruses. However, many findings are inconsistent. T/F 
viruses from subtypes A, C, and D appear to carry shorter and less glycosylated envelope 
glycoproteins (Env) [1,9,10], but this trend was not observed in subtype B viruses [5,11,12]. 
Clade B T/F viruses were reported to be more sensitive to neutralizing antibodies (NAbs) that 
target the CD4 binding site [12], but this was not observed for subtype C viruses [10]. On the 
other hand, subtype C T/F viruses were found to be more sensitive to antibodies obtained 
from their infecting donor [1], but this was not observed in a subtype B cohort [11]. Several 
studies have shown that almost all T/F viruses use the CCR5 co-receptor and require high 
levels of CD4 to infect cells [3,10,13–16], even if T/F viruses appear to be more restricted in 
the use of various CCR5 conformations than chronic viruses [10,17]. Recent papers suggested 
that dendritic cells or immature Langerhans cells mediate the selective transmission of CCR5-
using viruses during their penetration through the mucous membrane barriers [18,19]. T/F 
viruses appear also to be modestly more resistant to the fusion inhibitor T1249 than chronic 
viruses [3], but this was not observed using the fusion inhibitor enfuvirtide (T20) [20]. T/F 
viruses were reported to display enhanced binding to dendritic cells and to subsequently be 
more efficiently transferred to T cells than viruses derived from chronic infections [21], but 
this was not observed in another study [12]. It was also shown that T/F viruses exhibit 
enhanced infectious properties [21,22], but this trend was not observed in other studies [5,23]. 
Finally, it was suggested that the innate immune system, through type I interferons, may favor 
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the selection of interferon α (IFNα)-resistant viruses during transmission [21,22,24,25]. In 
contrast, other studies showed that T/F viruses were equally [23] or modestly more [5] 
sensitive to IFN-α than their linked donor isolates.  
Overall, except for CCR5 utilization, no phenotypic features are consistently linked to the 
transmitted variant. Conflicting findings may originate from differences in methodologies 
and/or study populations. Indeed, some studies examined only a limited number of 
transmission pairs using samples issued from the chronically infected donor and its linked 
receiver, while others used large sequence data sets of unlinked acutely- versus chronically 
infected patients. However, we cannot exclude that stochastic effects may also contribute to 
the transmission bottleneck and that any sufficiently fit R5 virus might be transmitted. 
To better understand whether the transmission bottleneck is mainly stochastic or if viral 
variants with particular biological properties are selected at transmission, we used another 
approach based on the comparison of the antigenic and functional properties of transmitted 
viruses that have a common origin, derived from eight transmission clusters. We hypothesized 
that, if the transmitted variants within a transmission cluster have a selective advantage, they 
should share some phenotypic characteristics. Moreover, if some properties are conserved 
between all the variants irrespective of the cluster to which they belong, they should favor 
their transmission.  
METHODS 
Study population 
The HIV-1 population was derived from plasma samples collected at time of or very early 
after primary infection from patients enrolled in the ANRS PRIMO cohort [26]. The patients 
were 27 Caucasian men having sex with men (MSM), infected by clade B (six clusters, 21 
patients) or CRF02-AG (two clusters, six patients) viruses between 2006 and 2013 
(Supplemental Table 1, http://links.lww.com/QAD/B314). They segregated into eight 
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transmission clusters identified by strong similarity of the pol gene (genetic distance < 
0.015%) and phylogenetic analyses (bootstrap of the cluster > 98%) [27]. All patients were 
antiretroviral-naive at the time of enrollment in the cohort. The estimated date of infection 
was defined as the date of symptom onset minus 15 days for patients with symptomatic 
primary infection, or, for asymptomatic patients, the date of the incomplete western blot 
(presence of antibodies to gp160 and P24) minus 1 month or the midpoint between a negative 
and a positive ELISA result [26]. National ethics committee approvals were obtained for the 
cohort [Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale 
(CCPPRB) Paris-Cochin and Comité de Protection des Personnes (CPP) Ile de France III] and 
all patients gave written informed consent to participate in the cohort.  
Production of pseudotyped viruses, titration, and analysis of their Env content  
Env-pseudotyped viruses were produced as described previously [28]. For the analysis of the 
Env content, viral particles were overlaid on a 20% sucrose cushion and pelleted at 87,000 x g 
for 1.5 h at 4°C. Viral pellets were solubilized overnight at 4°C in 100 µl PBS supplemented 
with 1% Triton X-100 and an antiprotease cocktail. P24 antigen content was determined by 
ELISA (INNOTEST® HIV Antigen mAb; Innogenetics). The Env ELISA was performed in 
Nunc Maxisorp plates (Dutscher). A pool of three HuMoNAbs (PGT145, b12, PGT128) was 
used for the detection of Env captured on D7324 (Aalto Bioreagents Ltd., Dublin, Ireland)-
coated microplates. Dilutions of purified gp120IIIB (Advanced Bioscience Laboratories) were 
used to construct a standard curve. 
Viral infectivity in TZM-bl cells 
Viral infectivity was determined in quadruplicate in TZM-bl cells. Samples of 100 µL virus 
stock, normalized to 25 ng P24 were added to 100 µL culture medium. Aliquots of 1 x 104 
TZM-bl cells were added to viruses in the presence of 30 µg/mL DEAE-dextran. Infection 
levels were determined after 48 h by measuring the luciferase activity of cell lysates using the 
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Bright-Glo luciferase assay (Promega) and a Centro LB 960 luminometer (Berthold 
Technologies). 
Neutralization assay 
The sensitivity to neutralization of pseudotyped viruses was probed in TZM-bl cells using 
HuMoNAbs PG9, PGT145, NIH45-46G54W, 3BNC117, 10-1074, PGT121, 10E8 and 
8ANC195 (IAVI and NIH AIDS Reagent Program), as described previously [28]. 
Determination of co-receptor usage 
Co-receptor usage was determined using U373 MAGI cells (NIH AIDS Reagent Program) 
stably expressing CD4 and either CCR5 or CXCR4, as described previously [29]. 
Inhibition of entry by Enfuvitide, CCR5 antagonists, and CD4 analogs. 
TZM-bl cells were used in duplicate to assess the sensitivity of pseudotyped viruses to the 
fusion inhibitor enfuvirtide (T20), CCR5 antagonist MVC, and CD4 inhibitors sCD4, sCD4-
183 (NIH AIDS Reagent Program), and M48U1 (provided by L. Martin, CEA, Gif sur Yvette, 
France). After titration, pseudotyped virus stocks were diluted to obtain 400 TCID50/mL in 
growth medium. Aliquots of 50 µL were then incubated for 1 h at 37°C with 50 µL of three-
fold serial dilutions of T20, sCD4, sCD4-183 or M48U1 (10 µg/mL to 0.0046 µg/mL). The 
virus-inhibitor mixture was then used to infect 1 x 104 TZM-bl cells in the presence of 30 
µg/mL DEAE-dextran. Infection levels were determined after 48 h by measuring the 
luciferase activities of cell lysates. IC50 values were defined as the inhibitor concentration 
reducing RLUs by 50%. Results were expressed as mean duplicate values. 
For MVC inhibition, 8 x 103 TZM-bl cells per well were plated the day before infection. Cells 
were first treated for 1 h at 37°C with 150 µL three-fold serial dilutions of MVC (6 µM to 0.3 
nM) before adding 50 µL pseudotyped viruses normalized to 400 TCID50/mL. One hundred 
microliters DMEM medium, supplemented with 30 µg/mL DEAE-dextran, was then added to 
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the cells. Luciferase activity was measured 48 h after infection as described above. CCR5 
antagonist susceptibility is expressed as the maximal percent inhibition (MPI) and IC50 values. 
Sanger Sequence analysis 
All full-length env PCR products were sequenced according to the Dye Terminator cycle 
sequencing protocol (Applied Biosystems, Foster City, Calif.). All sequences have been 
submitted to GenBank and assigned accession numbers MH000288 to MH000314. Nucleotide 
sequences were aligned using CLUSTALW and manually edited. Potential N-linked 
glycosylation sites (PNGS) were identified using the N-Glycosite tool at the HIV LANL 
database website (http://www.hiv.lanl.gov). A maximum likelihood tree was computed with 
RAxML, using the GTRGAMMA model of nucleotide substitutions with bootstrap analysis to 
assess branch support (1,000 replicates). We conducted a BLAST search to identify the 10 
most closely related sequences available in Genbank for each sequence. After excluding 
duplicate sequences, these sequences were downloaded and included in the phylogenetic 
analysis. Mean intra-cluster p-distances, i.e. the proportion of nucleotide differences between 
two sequences in a cluster, were calculated using MEGA7. 
RESULTS 
Studied population. 
Blood samples of selected patients were collected less than three months post-infection. The 
variants that we analyzed were therefore considered to be early/transmitted viruses. The 
maximum window periods for transmission after primary infection were estimated by 
determining the time interval between the first and last infection within each cluster 
(Supplemental Table 1, http://links.lww.com/QAD/B314). Transmission intervals ranged 
from 0.4 to 37.6 months, with a median transmission interval of 17.1 months (IQR 5–35.5).  
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Comparison of nucleotidic env and deduced amino-acid Env sequences  
Full length env sequences of the transmitted viral population infecting each subject were 
obtained by sequencing of bulk env PCR products. We compared the 27 sequences to the 140 
most closely related env sequences available in Genbank. Phylogenetic analyses confirmed 
that the env sequences from the selected patients grouped into eight clusters (bootstrap value 
of 100%), including six clusters of subtype B and two clusters of CRF02-AG env sequences. 
Within each cluster, the mean p-distance was low, ranging from 0.005 to 0.093 nucleotide 
substitutions per site (Figure 1). 
Because it was previously suggested that short length and low number of PNGS of gp120 
variable regions were characteristics of T/F viruses [1,9,10], we looked at them in our 27 Env 
sequences (Table 1). Both length and number of PNGS differed between clusters. 
Surprisingly, although variants within each cluster were genetically closely related, a 
substantial diversity in length and number of PNGS of the variable regions was observed, 
except for the V3 region. Only variants of cluster 8 were highly homogeneous, with equal 
length, net charge, and PNGS for each variable region. Of note, the time interval between the 
first and last infection within this cluster was extremely short (11 days) (Supplemental Table 
1, http://links.lww.com/QAD/B314). 
Transmitted viruses belonging to the same cluster have similar neutralization profiles 
We generated pseudotyped viruses expressing Env variants representative of the viral quasi-
species infecting each patient and compared their sensitivity to neutralization by a panel of 
eight HuMoNAbs chosen to be representative of the five regions of vulnerability of the HIV-1 
envelope [30–44] (Table 2). Neutralization profiles were highly conserved within each cluster 
except for viruses of cluster 6, suggesting the transmission of variants with specific properties, 
even when the transmission events occurred at several months interval. Viruses of cluster 6 
differed from those of other clusters by their high resistance to almost all HuMoNAbs. 
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Disregarding variants of cluster 6, all transmitted viruses were susceptible to antibodies 
targeting V3, the CD4 binding site, and the MPER region, suggesting the transmission of 
viruses harboring these epitopes. The neutralization profiles, although similar within each 
cluster, were different between clusters. This observation suggests a conservation of specific 
properties within each cluster for the viruses to be transmitted, but conservations that can be 
different for each transmission chain. 
Inspection of HuMoNAb epitopes on Env sequences showed that most resistant viruses 
harbored mutations of essential residues (Supplemental Fig. 1, 
http://links.lww.com/QAD/B314). We observed a shift of the PNGS from N332 to N334 in all 
viruses of cluster 6 resistant to antibodies targeting V3 (Supplemental Fig. 1A, 
http://links.lww.com/QAD/B314), a shift of the PNGS from N234 to N230 in viruses of 
clusters 3, 4, and 6, resistant to 8ANC195 (Supplemental Fig. 1B, 
http://links.lww.com/QAD/B314), and the loss of N160 in viruses of clusters 6 and 7 that 
were resistant to both PG9 and PGT145 (Supplemental Fig. 1C, 
http://links.lww.com/QAD/B314). We did not find any potential relationship between the 
resistance of viruses to antibodies targeting the CD4 binding site and MPER region and the 
absence of specific residues at key positions. 
Transmitted viruses exhibit CCR5 tropism and are highly susceptible to maraviroc 
(MVC) 
We first determined the tropism of pseudotyped viruses by measuring their ability to 
efficiently infect CD4+/U373 MAGI cells expressing either the CXCR4 or CCR5 co-receptor 
[45]. All viruses infected exclusively CD4+/CCR5+/U373 cells, as expected (Supplemental 
Table 2, http://links.lww.com/QAD/B314).  
We then assessed the efficiency of CCR5 usage of Env-pseudotypes by infecting TZM-bl 
cells in the presence of decreasing concentrations of the CCR5 antagonist MVC (6000 nM to 
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0.3 nM). All pseudotyped viruses were highly susceptible to MVC with an IC50 < 10 nM and 
maximal percent inhibition (MPI) values above 90% in the presence of saturating 
concentrations of MVC (Table 3). 
Transmitted viruses are resistant to soluble CD4 but sensitive to a CD4-mimetic 
miniprotein 
We compared the efficiency of CD4 receptor usage of all pseudotyped viruses through their 
sensitivity to CD4 analogs. Most viruses were highly resistant to two soluble forms of CD4 
containing either all four (sCD4) or the first two (sCD4-183) extracellular domains, with IC50 
values > 10 µg/mL for 21 and 23 of 27 viruses, respectively (Table 3). In contrast, all 
pseudotyped viruses, except one variant of cluster 6, were sensitive to M48U1, a CD4 
mimetic miniprotein [46,47] (Table 3).  
We compared residues of the Phe-43 cavity and those known to interact with CD4 and/or 
M48U1 in the 27 Env sequences to identify potential molecular determinants of these 
differences (supplementary Figure 2, http://links.lww.com/QAD/B314) [32,46–49]. There 
were no significant differences between viruses resistant or sensitive to the two soluble forms 
of CD4. Comparison of the residues that interact with M48U1 showed that the only resistant 
virus (virus 275 of cluster 6) harbored a mutation of the conserved serine/threonine residue at 
position 375 to an isoleucine residue. The loss of this residue has already been described to 
disrupt the molecular interaction with M48U1 [47,50,51].  
Transmitted viruses are sensitive to the fusion inhibitor enfuvirtide (T20)  
We tested Env-pseudotyped viruses for their sensitivity to T20. By mimicking the activity of 
HR2, T20 binds to the HR1 domain of gp41, which becomes exposed after CD4/coreceptor 
engagement. Higher resistance to this fusion inhibitor may thus reflect faster fusion kinetics. 
All viruses were sensitive to T20 (IC50 range: < 0.00457 to 1.23 µg/mL), with conserved 
sensitivity levels within each transmission cluster (Table 3). 
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Transmitted viruses have similar infectious properties 
We compared the capacity of pseudotyped viruses to infect TZM-bl cells in a single round of 
infection. Infectivity levels of each pseudotyped virus, for which the input was normalized to 
the amount of P24, was evaluated 48 h post-infection by measuring luciferase activity (RLU). 
Infectivity levels were conserved within clusters, with a relative standard deviation (RSD) of 
log10 RLU < 15% for almost all clusters (Table 4). Only two clusters (clusters 2 and 6) 
displayed higher variability of infectivity levels (RSD of log10 RLU > 15%). Infectivity levels 
were also conserved between clusters, with log10 RLU means ranging from 5.59 to 6.65 and a 
global RSD of 10.71% for the 27 viruses. Since Env incorporation may be variable among the 
pseudotyped viruses, we determined the gp120 content of each viral stock and we assessed the 
infectivity after normalization for Env content. The four viruses of cluster 6 and one virus 
(virus 256) of cluster 2 harbored very low levels of gp120, under the detection limit of the 
ELISA test (Table 4). Except for these five viruses, we evaluated the infectivity of each 
pseudotyped virus normalized for Env content by dividing infectivity values by gp120 
content. Infectivity levels were again conserved, both within (RSD of log10 RLU < 10%) and 
between clusters (global RSD of 7.39 % for the 22 viruses for which the infectivity values 
could be normalized) (Table 4). Overall, these results show that transmitted viruses had 
similar infectious properties.  
DISCUSSION 
Previous studies have shown that generally a single HIV-1 variant from the diverse viral 
population in the transmitting partner establishes infection in the new host [2,3,5]. HIV-1 is 
clearly subjected to a stringent genetic bottleneck during transmission, but the extent to which 
this event is driven by specific properties of the transmitted viruses or is the result of a 
stochastic process remains to be determined. We analyzed the antigenic and functional 
properties of envelope glycoproteins of viral variants present during or very early after 
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primary infection in 27 patients belonging to eight transmission chains of at least three 
patients to better understand this phenomenon. Our strategy was based on the assumption that, 
if transmitted viruses share properties within a transmission chain, these would be indicative 
of a non-stochastic process and, if properties are conserved both within and between 
transmission clusters, these would reflect a selective advantage.  
Sequencing and phylogenetic analysis of env genes confirmed the close relation between 
viruses from a same transmission cluster. A detailed comparison of deduced Env amino-acid 
sequences revealed that the V1, V2, V4 and V5 regions differed in length, number of PNGS, 
and charge, despite the fact that the sequences were closely related within each cluster. Thus, 
transmitted variants, albeit closely related, differed between patients of the same transmission 
chain. Although we could assume that the viruses belonged a same transmission chain based 
on molecular evidences, a comparison of transmitted variants with viral populations 
circulating in the chronic phase of infection could not be done because almost patients were 
treated within a few months after their inclusion in the cohort. In addition, we did not have 
epidemiological data suggesting that there were direct links such as donor/receiver pairs 
within them. It can be hypothesized that some transmission events might have emerged from 
other individuals belonging to the chain, including chronically infected patients harboring a 
diversified viral population. This is supported by studies on MSM cohorts from different 
countries that estimated that only approximately 25% of transmissions occurred during the 
first six months of infection [52–54].  
We analyzed the antigenic profiles of the transmitted Env variants by measuring their 
sensitivity to a panel of representative HuMoNAbs targeting the five regions of vulnerability 
of the HIV-1 envelope. Although the transmitted variants were not identical, they shared 
similar profiles. Neutralization profiles were highly conserved within all but cluster 6, 
regardless of the HuMoNAb, suggesting that the transmission bottleneck is mainly driven by 
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a non-stochastic process. In addition, disregarding viruses of cluster 6, all transmitted viruses 
were susceptible to antibodies targeting V3, the CD4 binding site, and the MPER region, 
strongly suggesting the transmission of viruses harboring these epitopes. These results are in 
accordance with our previous study showing that the best combination of HuMoNAbs to 
efficiently neutralize recently transmitted viruses of subtype B was that targeting these three 
regions [55]. These HuMoNAbs should therefore be good candidates to limit HIV 
transmission in prophylactic approaches or vaccine strategies. However, a variant such that 
present in cluster 6 would be susceptible to escape to prophylaxis with this tri-specific 
combination. This observation, in addition to the fact that the HIV-1 species seems to evolve 
toward higher resistance to neutralization [28,55-57], argues for a global prospective 
surveillance of the susceptibility of HIV-1 to HuMoNAbs. 
We explored the functional properties of the transmitted viruses by next comparing their 
sensitivity to various entry inhibitors, including the MVC CCR5 antagonist, several CD4 
analogs, and the T20 fusion inhibitor. All viruses were CCR5-tropic and highly susceptible to 
MVC, suggesting that transmitted viruses are restricted to use CCR5 conformations that are 
sensitive to MVC. This result is in accordance with previous studies showing that transmitted 
viruses are less able to use a MVC-resistant form of CCR5 than viral variants found during 
chronic infections [10,17]. Although the biological significance of this phenomenon remains 
to be determined, it appears that the transmission bottleneck selects for viruses that are 
restricted in the use of the CCR5 co-receptor. Analysis of the sensitivity of transmitted viruses 
to two soluble forms of CD4 (sCD4 and sCD4-183) showed that most viruses were highly 
resistant to both forms (IC50 > 10 µg/mL), suggesting that their affinity for CD4 is low and 
consequently that they may require high levels of CD4 to efficiently infect target cells. In 
agreement with our results, several studies have shown that transmitted viruses are unable to 
efficiently infect cells expressing low levels of CD4 [14,15,58,59]. In contrast, all viruses 
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were highly sensitive to M48U1. The difference in response to exposure to either soluble 
forms of CD4 or M48U1 could be explained by the fact that M48U1 binds to gp120 with 
higher affinity than that of the CD4 protein [46,60]. This property is due to the presence of 
flexible hydrophobic extensions that fit into and stabilize the Phe-43 cavity, a critical element 
in the interaction between gp120 and CD4. Our result reinforces the potential use of M48U1 
as a new microbicide to prevent HIV-1 transmission [61]. Viruses were also highly sensitive 
to the fusion inhibitor T20, with conserved sensitivity levels within each cluster reinforcing 
the hypothesis that the transmission bottleneck is a non-stochastic event. 
We also analyzed the infectivity of transmitted viruses in a single round of infection of TZM-
bl cells. Except for a few viruses, transmitted viruses shared similar infectious properties, 
regardless of whether the input normalization was based on P24 or Env incorporation levels. 
Infectivity levels were in the same range as those of regularly used laboratory strains, NL4-3 
or AD8, suggesting that the transmission bottleneck did not select for particularly highly 
infectious Env variants.  
In conclusion, our study shows that transmitted viruses from the same transmission chain 
share similar phenotypic properties. It is impressive to see that viruses from a same cluster 
have similar neutralization profiles and sensitivity to various inhibitors, even when viruses are 
transmitted at several months or years interval and possibly after passages through various 
intermediate hosts. It suggests that the conservation of biological properties for a given 
variant to be successfully transmitted is a necessity. It seems to us that this phenomenon is a 
strong argument to suggest that the transmission bottleneck is mainly non-stochastic but 
involves specific properties conferring a selective advantage. In addition, some properties 
were conserved between all viruses, regardless of the cluster they belong. They were CCR5-
tropic, sensitive to MVC, and resistant to soluble forms of CD4, reinforcing previous studies 
showing the restrictive use of CCR5 and the requirement of high levels of CD4 of transmitted 
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viruses. They were also sensitive to HuMoNAbs targeting V3, the CD4 binding site, and the 
MPER region, suggesting that the loss of these functionally important regions might 
compromise their fitness and transmission capacity. Taken together, our results argue for the 
necessity for a variant to harbor specific phenotypic properties to be able to be transmitted. 
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Table 1: Length (aa number), number of PNGS and net charge of gp120 variable 
regions. 
Clust
er 
Viru
s 
V1 V2 V3 V4 V5 
Leng
th 
PNG
S 
Char
ge 
Leng
th 
PNG
S 
Char
ge 
Leng
th 
PNG
S 
Char
ge 
Leng
th 
PNG
S 
Char
ge 
Leng
th 
PNG
S 
Char
ge 
 
HX
B2 27 2 0 39 2 1 36 1 10 34 4 -3 10 1 -1 
1 
242 31 3 1 39 2 0 35 1 6 33 4 -6 10 2 0 
244 31 4 3 39 2 1 35 1 7 33 5 -3 10 2 0 
246 31 4 3 39 2 1 35 1 7 33 5 -3 10 2 0 
248 38 6 2 39 2 1 35 1 7 33 5 -3 10 2 0 
2 
256 23 2 0 47 3 1 35 1 5 30 4 0 12 2 -1 
257 24 2 0 45 3 0 35 1 5 30 3 -1 12 2 0 
258 27 3 -1 40 2 2 35 1 5 30 3 1 12 1 -1 
259 27 3 -1 45 3 3 35 1 5 30 3 1 12 2 -1 
3 
260 23 2 0 39 2 2 35 1 5 31 5 -2 10 1 -1 
261 26 3 0 41 2 1 35 1 6 39 7 -1 9 2 -1 
263 25 2 1 39 3 1 35 1 5 36 6 -4 9 1 0 
4 
265 31 4 -1 41 2 1 35 1 5 32 6 -2 14 2 0 
267 28 3 0 39 2 1 35 1 3 32 5 -1 11 2 0 
268 31 5 1 41 2 1 35 1 5 35 6 -2 14 2 -1 
5 
269 22 2 0 39 2 0 35 1 5 29 5 -1 10 1 -1 
271 30 3 -1 39 2 2 35 1 5 30 6 -2 10 1 0 
274 30 3 -1 39 2 2 35 1 5 30 6 -2 10 1 0 
6 
275 33 4 -1 38 1 3 35 1 3 34 5 0 9 1 -1 
276 35 4 -2 39 2 0 35 1 5 34 5 1 9 1 0 
277 35 4 -3 39 2 1 35 1 5 34 5 0 11 1 1 
278 35 5 0 39 2 0 35 1 7 36 4 -2 10 2 -1 
7 
279 15 1 1 44 2 2 35 1 4 31 3 2 10 1 -2 
282 12 1 -1 44 1 1 35 1 4 31 4 0 13 2 -1 
280 18 1 -2 44 2 1 35 1 4 29 5 0 10 1 -2 
8 
168 27 5 -1 41 2 3 35 1 3 35 6 -1 10 2 0 
169 27 5 -1 41 2 3 35 1 3 35 6 -1 10 2 0 
170 27 5 -1 41 2 3 35 1 3 35 6 -1 10 2 0 
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Table 2: Sensitivity of transmitted viruses to neutralization by HuMoNAbs. 
 
  
Clust
er 
Vir
us 
CD4bs V1V2 V3 MPER gp120/gp41 
3BNC117
IC50 
(g/mL) 
NIH45-
46G54W 
IC50 
(g/mL) 
PG9 
IC50 
(g/mL)
PGT145
IC50 
(g/mL)
10-1074
IC50 
(g/mL)
PGT121
IC50 
(g/mL)
10E8 
IC50 
(g/mL) 
8ANC195
IC50 
(g/mL)
1 
242 0.06 0.03 >10.0 0.23 < 0.005 < 0.005 0.39 1.72 
244 0.10 0.12 8.13 0.08 0.01 < 0.005 0.49 0.83 
246 0.09 0.11 7.66 0.12 0.01 < 0.005 0.9 1.28 
248 0.05 0.08 >10.0 0.14 0.03 0.02 0.74 1.76 
2 
256 0.22 0.08 0.33 0.04 0.09 0.06 0.25 0.35 
257 1.71 0.66 0.11 0.05 0.09 0.08 0.11 0.68 
258 0.85 0.29 0.63 0.06 0.11 0.11 0.07 0.89 
259 0.84 0.20 0.83 0.03 0.23 1.04 0.05 1.08 
3 
260 0.07 0.02 0.04 >10.0 0.01 < 0.005 0.54 >10.0 
261 0.09 0.02 2.10 >10.0 0.03 0.15 1.62 >10.0 
263 0.10 0.11 0.46 >10.0 0.01 0.42 0.61 >10.0 
4 
265 0.78 0.11 >10.0 0.24 0.06 0.03 0.29 >10.0 
267 0.08 0.02 6.58 0.40 0.03 0.01 0.38 >10.0 
268 0.66 0.09 >10.0 1.01 0.08 0.01 2.95 >10.0 
5 
269 0.51 0.31 0.11 0.01 0.02 0.01 0.1 1.04 
271 0.04 0.07 5.01 0.02 0.05 0.02 0.43 1.89 
274 0.06 0.08 1.64 0.01 0.02 0.01 0.31 1.26 
6 
275 0.36 0.01 >10.0 >10.0 >10.0 2.19 3.25 >10.0 
276 >10.0 8.35 2.25 2.54 >10.0 >10.0 2.02 >10.0 
277 >10.0 8.21 8.15 1.02 >10.0 9.28 0.71 >10.0 
278 >10.0 9.56 8.22 0.81 >10.0 >10.0 >10.0 >10.0 
7 
279 0.10 0.05 >10.0 >10.0 < 0.005 < 0.005 0.02 1.79 
280 0.31 0.17 >10.0 >10.0 0.04 < 0.005 0.12 2.35 
282 0.08 0.07 >10.0 >10.0 0.01 < 0.005 0.24 3.26 
8 
168 0.61 2.11 0.05 3.67 0.55 3.43 2.49 0.83 
169 0.36 2.61 0.09 6.21 0.28 2.21 1.1 0.35 
170 0.35 2.27 0.09 3.41 0.34 2.31 2.83 0.97 
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Table 3: Sensitivity of transmitted viruses to entry inhibitors 
Cluster Virus MVC  sCD4-183 sCD4 M48U1 T20 IC50 (nM) MPI (%) IC50 (g/mL)IC50 (g/mL)IC50 (g/mL)IC50 (g/mL)
1 
242 0.52 95.5 > 50.0 > 50.0 < 0.005 0.67 
244 1.03 95.4 11.3 29.0 < 0.005 0.76 
246 1.00 99.0 17.0 43.1 < 0.005 0.31 
248 0.76 97.4 31.9 13.9 0.02 0.34 
2 
256 0.67 97.0 27.7 >50 0.33 0.58 
257 1.95 98.5 14.1 21.3 0.06 0.09 
258 1.09 97.8 9.80 11.3 0.34 0.16 
259 1.45 96.4 22.0 > 50.0 1.44 0.21 
3 
260 1.79 98.5 17.5 14.7 0.02 < 0.005 
261 1.05 99.0 17.8 > 50.0 0.01 < 0.005 
263 1.14 99.0 1.70 1.49 < 0.005 < 0.005 
4 
265 < 0.30 98.5 > 50.0 31.2 0.10 0.01 
267 < 0.30 99.9 12 11.4 0.01 0.02 
268 0.71 99.5 28.8 13.7 0.07 0.04 
5 
269 0.40 99.5 3.90 1.81 < 0.005 0.01 
271 1.03 99.7 12.2 1.16 < 0.005 0.01 
274 0.94 99.4 14.8 25.1 0.04 0.01 
6 
275 1.59 97.2 > 50.0 40.8 > 10.0 0.20 
276 1.10 98.5 12.0 12.5 0.94 0.14 
277 0.33 99.2 11.1 6.38 0.98 0.06 
278 1.33 98.5 3.70 1.39 0.33 0.08 
7 
279 0.99 96.4 38.0 26.3 0.40 0.01 
280 1.21 96.5 0.18 0.50 < 0.005 0.01 
282 1.28 98.3 40.0 14.4 0.29 0.02 
8 
168 1.25 97.5 22.0 40.5 0.06 0.48 
169 0.79 97.8 46.4 26.8 0.04 0.21 
170 1.25 99.3 31.9 36.8 0.10 0.49 
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Table 4: Infectivity of transmitted viruses 
Clusters Virus 
Infectivity 
(log10 RLU/25 
ng P24 
Mean log10 
RLU/25 ng P24 
(RSD) 
Env content 
(ng Env/25 
ng P24) 
Infectivity 
(log10 RLU/1 
ng Env) 
Mean log10 
RLU/1 ng Env 
(RSD) 
1 
242 6.52 
6.65 (4.20) 
0.6029 6.74 
6.95 (2.56) 244 6.41 0.2418 7.02 246 6.63 0.5680 6.88 
248 7.05 0.7890 7.15 
2 
256 6.46 
6.25 (16.1) 
<0.0002 na 
na 257 7.34 1.1827 7.26 258 4.90 0.0060 7.12 
259 6.32 0.4422 6.68 
3 
260 6.02 
6.22 (4.50) 
0.0876 7.07 
7.14 (0.93) 261 6.11 0.0910 7.15 
263 6.54 0.2158 7.21 
4 
265 5.79 
6.23 (11.8) 
0.2835 6.33 
6.77 (9.40) 267 5.83 0.2275 6.48 
268 7.08 0.3811 7.50 
5 
269 5.02 
5.72 (10.7) 
0.2465 5.62 
5.99 (5.31) 271 6.11 0.7789 6.21 
274 6.05 0.8501 6.12 
6 
275 7.44 
6.24 (16.3) 
<0.0002 na 
na 276 6.66 <0.0002 na 277 5.70 <0.0002 na 
278 5.14 <0.0002 na 
7 
279 5.49 
5.59 (4.62) 
0.0088 7.55 
7.50 (1.66) 280 5.89 0.0110 7.36 
282 5.40 0.0194 7.60 
8 
168 6.59 
6.50 (2.41) 
0.5768 6.83 
6.77 (3.22) 169 6.59 0.4430 6.95 
170 6.32 0.6229 6.53 
RSD : relative standard deviation (%) ; na : not applicable 
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